drugset / Trial / NCT02209688
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESR 1150 CL in Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
The objective of this study was to obtain safety and tolerability data and first pharmacokinetic and pharmacodynamic data of escalating doses of ESR 1150 CL.
Timeline
- Start
- 2000-02
- Primary completion
- 2000-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ESR 1150 CL | Unknown | 0.5 mg | — |
| Subject | ESR 1150 CL | Unknown | 1 mg | — |
| Subject | ESR 1150 CL | Unknown | 2 mg | — |
| Subject | ESR 1150 CL | Unknown | 4 mg | — |
| Subject | ESR 1150 CL | Unknown | 8 mg | — |
Indications
No indication recorded.